Upcoming events

    • April 13, 2024
    • 8:00 AM (PDT)
    • April 13, 2025
    • 6:00 PM (PDT)

    Welcome to 2024 CAN Program and thank you for sponsoring and exhibiting!

    This is Step 1. 

    To become a sponsor or exhibitor of 2024 CAN Program, please follow the steps below:

    1. Click the "Sponsor/Register" button at the right-corner and follow the step-by-step process to pay. The price will differ depends on level of sponsorship. Two payment methods:

    A. Pay by credit card.

    B. Pay by check. Click "invoice me" and then print out the invoice in your email. Mail the invoice together with the a check (payable to "CABS") to the following address: 268 Bush Street, #1888, San Francisco, CA 94104. U.S.A.

    2. You will receive an email to confirm your payment. High level sponsors will get free guest conference admission passes. Please go to Step 2 to register yourself and free guests for conference admission. 

    Please contact fundraising@cabsweb.org if you have any question!

    • September 07, 2024
    • 8:00 AM (PDT)
    • September 07, 2025
    • 6:00 PM (PDT)
    • South San Francisco Convention Center
    Registration is closed

    Welcome to 2024 BioPacific Conference  and thank you for sponsoring and exhibiting!

    This is Step 1. 

    To become a sponsor or exhibitor of 2024 CABS BioPacific Conference, please follow the steps below:

    1. Click the "Sponsor/Register" button at the right-corner and follow the step-by-step process to pay. The price will differ depends on level of sponsorship. Two payment methods:

    A. Pay by credit card.

    B. Pay by check. Click "invoice me" and then print out the invoice in your email. Mail the invoice together with the a check (payable to "CABS") to the following address: 268 Bush Street, #1888, San Francisco, CA 94104. U.S.A.

    2. You will receive an email to confirm your payment. High level sponsors will get free guest conference admission passes. Please go to Step 2 to register yourself and free guests for conference admission. 


    Any question? Please contact: fundraising@cabsweb.org  

    • March 03, 2025
    • 7:30 AM (PST)
    • August 18, 2025
    • 6:00 PM (PST)
    • Online Zoom Conference

    Welcome to 2022 BioPacific Conference  and thank you for sponsoring and exhibiting!

    This is Step 1. 

    To become a sponsor or exhibitor of 2022 CABS BioPacific Conference, please follow the steps below:

    1. Click the "Sponsor/Register" button at the right-corner and follow the step-by-step process to pay. The price will differ depends on level of sponsorship. Two payment methods:

    A. Pay by credit card.

    B. Pay by check. Click "invoice me" and then print out the invoice in your email. Mail the invoice together with the a check (payable to "CABS") to the following address: 268 Bush Street, #1888, San Francisco, CA 94104. U.S.A.

    2. You will receive an email to confirm your payment. High level sponsors will get free guest conference admission passes. Please go to Step 3 to register yourself and free guests for conference admission.

    Any question? Please contact: fundraising@cabsweb.org   


    • March 04, 2025
    • May 15, 2025
    • 10


    The Chinese American Biopharmaceutical Society (CABS) is thrilled to announce a new summer internship program focused on the cutting-edge field of data science applied to drug discovery and development.

    As our industry generates unprecedented amounts of data from genomics, proteomics, clinical trials and real-world evidence, there is a growing need for talented data scientists who can derive insights to drive innovation. CABS is committed to helping bridge this talent gap and train the next generation of data leaders in biopharma.

    This 10-week non-paid internship program will provide an immersive experience for undergraduate and graduate students to work alongside data science teams at top CABS member companies in the San Francisco Bay Area. Interns will get hands-on experience applying the latest machine learning, AI and data analytics tools to solve real-world challenges across all phases of the drug development lifecycle.

    Not only will interns gain technical data skills, but they will also learn about the biopharma business through workshops, networking events, and mentorship opportunities with CABS member company leaders, entrepreneurs and investors.

    A primary focus will be nurturing a talented and diverse pipeline of data science professionals, including those from Asian American and Pacific Islander backgrounds. In addition to students from top universities like UC Berkeley, Stanford and UCSF, we strongly encourage applications from students at universities across the Pacific Rim and Asia. 

    Internship Timeline:

    - Applications Open: Feb 15th, 2025

    - Application Deadline: May 15th, 2025

    - Internship Dates: June 15 - August 25, 2025

    This internship program represents an incredible professional development opportunity. We invite all eligible students passionate about life sciences and data to apply!

    For more details on the program, eligibility requirements and how to apply, please contact:

    sihongz@gmail.com,

    kaymeikuentong@gmail.com or

    shicheng.guo@cabsweb.org

    Please click this link or scan the QR code below

    to finish the online application!

    We look forward to receiving applications from the world's brightest data science minds!

    Sincerely,

    President, CABS

    Feb 02, 2025


    CABS 2025 Mentor Recruitment – Data Science Intern Program

    The Chinese American Biopharmaceutical Society (CABS) is excited to announce our new summer internship program focused on data science in drug discovery and development. As our industry produces vast amounts of data from genomics, proteomics, clinical trials, and real-world evidence, there is a critical need for experienced professionals to mentor the next generation of data science talent in biopharma.

     
    This 10‑week, non‑paid internship program offers undergraduate and graduate students a unique opportunity to work alongside data science teams at CABS member companies in the San Francisco Bay Area. While interns will gain hands-on technical experience with AI, machine learning, and analytics tools, your mentorship will uniquely empower them to navigate real-world challenges and accelerate their career growth.

     
    As a mentor, you will have the opportunity to:
    • Share your expertise and real‑world experience with passionate students.
    • Shape the future of data science and drug development.
    • Enhance your leadership skills by developing and refining your coaching abilities.

    Program timeline:
    • Applications Open: Feb 17, 2025
    • Application Deadline: May 15, 2025
    • Internship Dates: June 15 – August 25, 2025


    Please note: The CABS data science summer internship is fully remote, with no on-site requirements.

    Please click this link or scan the QR code below

    to finish the online application!

    If you’re eager to contribute to the development of future data science leaders and share your knowledge, please complete this application. We look forward to welcoming you as a mentor!


    For any questions, please contact: kay.tong@cabsweb.orgshicheng.guo@cabsweb.org or zuolincheng166@gmail.com




    • March 04, 2025
    • 8:00 AM (PST)
    • September 13, 2025
    • 8:00 PM (PST)
    • South San Francisco Conference Center

    2025 CABS BioPacific Annual Conference 

    Nomination For K. Fong Award in Life Sciences

    Deadline for nomination: April 30, 2025 

    The CABS K. Fong Award in Life Sciences is presented annually to recognize individuals who have made significant contributions to the life sciences and biopharmaceutical industries. This includes:

    • Outstanding scientific discoveries.

    • Notable efforts in promoting life science education.

    • Initiatives that enhance the life science community.

    • Therapeutic breakthroughs that bring new treatments to market and improve healthcare and quality of life.

    Nomination Process:

    • Candidates must be nominated by an active CABS member.

    • Nominees should have a certain level of involvement in CABS activities previously.

    • Selection will be based on the candidate’s overall accomplishments and contributions to the life science community, including one or more of the following:

      • Proven achievements in therapeutic breakthroughs (e.g., discovery, process, or clinical development), diagnostics, or the research reagent/equipment markets.

      • Significant contributions to the advancement of academic and industrial R&D in biomedical sciences and applications.

      • Notable involvement in the CABS community and efforts in promoting international collaboration in life sciences.

    Winners will be selected by the CABS Award Selection Committee. The recipient(s) will receive a Plaque of Merit at CABS BioPacific Annual Conference on September 13, 2025, at the South San Francisco Convention Center.

    About Dr. Kenneth Fong

    Dr. Kenneth Fong is a renowned entrepreneur, investor, and mentor to many biotech founders. He is a dedicated community leader and philanthropist with significant contributions to higher education and the biotech industry. Currently, Dr. Fong serves as the Chairman of Kenson Ventures, LLC—a venture capital firm specializing in financing and strategic consulting for biotech companies. He is also the founder and former CEO of Clontech, which developed and marketed molecular biology products to academic and pharmaceutical laboratories in the United States and 30 other countries. In addition, he serves on the boards and advisory boards of several biotech organizations in the US, China, Taiwan, and Hong Kong.

    Dr. Fong’s community and philanthropic activities include:

    • Establishing the Fong Optometry and Medical Library at UC Berkeley.

    • Creating the Fong Scholarship Programs and Annual Scientific Symposia at San Francisco State University.

    • Initiating the Annual Fong-Clontech Seminar Series at Indiana University.

    • Serving as Chairman of the San Jose Chinese Performing Arts Center (2000–2002).

    • Supporting the Chinese Historical Society of America (San Francisco, 2000) and pioneering the Biotech Program at the San Jose Tech Museum (1999).

    More recently, Dr. Fong has been actively supporting educational programs for children in under-served and impoverished regions of China. He is a member of Committee 100 and a former board member of the 80-20 Initiative. Currently, Ken dedicates much of his time to cultivating and advising entrepreneurs in the biotech industry, particularly those in the 40–55 age group.


    Past recipients of CABS K. Fong Awards

    2024: Dr. Zach Sweeney, Venture Partner at Versant Ventures, CEO and co- founder of Interline Therapeutics, CSO at Denali Therapeutics

    2023: Dr. Corey Goodman, Managing Partner at venBio, member of National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, a recipient of Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize, and Gruber Prize in Neuroscience. Co-founder of Exelixis, CEO of Renovis, President at Pfizer.

    2022: Dr. Scott Liu, Founder and CEO, HanchorBio Inc. (Co-Founder and former CEO, Henlius)

    2021: Dr. Xian-Ping Lu, Founder, Chairman and CEO, ChipScreen BioSciences Co.

    Dr. John O. Link, Former VP, Gilead Sciences, Inc (Retired)

    2019: John Oyler, MBA, Founder, CEO and Chairman of BeiGene

    2018: Dr. Guoliang Yu, Executive Chairman, Crown Bioscience, Venture Partner, OrbiMed Venture

    Dr. Yuling Luo, Founder,Chairman and CEO, Alamar Bioscience

    2017: Dr. Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in    leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that is completely developed in China.

    Dr. Edgar Engleman, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.

    2016: Dr. Gerald Chen, Co-founder of Morningside, for his extraordinary vision  and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

    2015: Dr. Irving Weissman, of Stanford University, for his pioneering research in stem cell research.

    2014: Dr. Ge Li, Founder and CEO of Wuxi Apptec, for creating and shaping      the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and Iopinavir.

    2013: Dr. Peter Hirth, Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market 

    Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.




    • March 07, 2025
    • 8:00 AM (PST)
    • March 07, 2026
    • 8:00 PM (PST)

    CABS, a certifying organization of President’s Volunteer Service Award (PVSA)

    On March 7, 2025, Chinese American Bio/Pharmaceutical Society (CABS) was officially approved as a certifying organization empowered to confer the President’s Volunteer Service Award (PVSA). CABS will be responsible for verifying and certifying that volunteers have fulfilled the necessary requirements to qualify for the PVSA within a 12-month period.

    Any eligible adult or student volunteer who has contributed to CABS events will be required to self-track their hours on the service log sheet. The co-chairs of each committee will oversee the review and verification process. It is imperative that volunteers diligently maintain their hours tracking records as proof during potential audits. Please use the “PVSA Service Log” as a template.

    For any inquiries or clarifications, please reach out to O2 Chair: Liang He, PhD; heliangsu2018@gmail.com


    The President's Volunteer Service Award

    President's Volunteer Service Award - Wikipedia

    We are currently seeking sponsors to support this impactful event. If your organization is interested in partnering with us, please reach out via email at fundraising@cabsweb.org.


    • March 17, 2025
    • 12:00 AM (PDT)
    • March 17, 2026
    • 11:59 PM (PDT)

    Dear everyone,

    Greetings from the Chinese American Biopharmaceutical Society (CABS), Business and Career Development committee!

    Building upon the success of the CAN (Career Advisory Network) program last year, we have decided to launch the program again this year. We would like to extend a sincere invitation to you to join us as either a mentor or a mentee.

    The goal of CAN is to foster the development of future life sciences professionals and leaders through mentoring, skill enhancement, and networking platform, and also provide opportunities to give back to the community. The program runs for a period of six months and offers one-on-one mentoring sessions, as well as small and large group networking events. If you have any questions or concerns, please contact Feng Pan (fengpan.fox@gmail.com) or Jonathan Wong (jwong@enigmarecruiters.com).

    Program is scheduled to be formally launched on April 19 with a kick off meeting. Below is a tentative schedule:

          Mentor/Mentee registration opens: Monday, 3/17/2025

          Registration closes: Monday, 3/31/2025

          Program acceptance, notification emails sent: Monday, 4/7/2025

          Kick-off event: Saturday, 4/19/2025

          Mentoring groups convene: May to October

          Graduation: TBD

    Please visit http://www.cabsweb.org/can/ to learn more about CAN program. If you are interested in becoming a mentor or mentee, please complete the forms below.

          MENTOR registration:

    https://docs.google.com/forms/d/e/1FAIpQLSee9jAhkqnFaRMvI9l_ijafqBXsNFSj1X3a6ix6O5Au6Zhd8Q/viewform?usp=header 

          MENTEE application:

    https://docs.google.com/forms/d/e/1FAIpQLSfAq9pJM9wyVyGKsHtMf8kMsLuRRt-5bCXNpaSWLRJ6OBUb4Q/viewform?usp=header

    Please use the link or QR code above to register as a mentor or apply as a mentee.

    • April 12, 2025
    • 9:30 AM - 1:00 PM (PDT)
    • 1633 Old Bayshore Hwy #280, Burlingame, CA 94010
    • 81

    Begin With the End in Mind – Part 1: What Should I Know About Commercialization If I’m Not Planning to Launch a Product Myself?

    In parallel with the scientific roadmap of drug discovery and development, a commercial roadmap also plays a critical role. While commercialization and product launch may seem like separate domains for scientists and startup founders, adopting a commercial mindset early on is essential for success.

    So, what aspects of commercialization should I be aware of?

    • If you are a translational scientist, how does commercialization connect with clinical development? What commercial considerations should you keep in mind when developing a Target Product Profile (TPP)? How do you translate scientific differentiation into clinical differentiation—and ultimately, commercial differentiation?

    • If you are a startup founder, what commercial value should you highlight in your pitch deck? How do you generate key insights, such as market analysis?

    • If you are a biotech executive, how do commercial considerations influence overall company strategy?

    • Or perhaps you are simply interested in exploring a career in the commercial side of biotech and pharma!

    Agenda:

    9:30 - 10:00 AM | Check-in & Networking
    10:00 - 11:00 AM | Fireside Chat: Understanding Key Commercial Concepts – What Do These Terms Really Mean?
    11:00 - 12:00 PM | Panel Discussion: Commercial positioning, Market Research, Forecasting, Marketing, Market Access, Medical Affairs, and Pricing
    12:00 - 1:00 PM | Lunch & Networking

    Speaker:

    Alvin Lin, MBA

    Alvin (Al) Lin is Vice President of Commercial Strategy at Vera Therapeutics. His experience includes lifecycle leader, new product planning, portfolio management, BD valuations, market access, marketing, field sales, and commercial operations. He has commercialized medicines including IMBRUVICA (ibrutinib) and SOLIRIS (eculizumab) and has launched multiple products into US and exUS markets.  He has worked in the past at Merck, Pharmacyclics, and Alexion, and has degrees from Cornell, MIT, and the Tufts School of Medicine.

    Connie Tat, Ph.D.

    Senior Medical Science Director, Oncology

    Genentech  

    Connie is a strategic biopharmaceutical operator with nearly a decade of diverse experiences across discovery, development and commercialization at globally successful companies. At Genentech, she set the strategic direction of the GU oncology portfolio and advanced the execution of clinical trials (including research collaborations) towards commercialization within the U.S. healthcare ecosystem. Previously, she led regional cross functional teams on the launch of LUMAKRAS at Amgen and worked in competitive intelligence at Exelixis. Prior to Exelixis, Connie worked in biotech equity research at SunTrust Robinson Humphrey in NYC and consulted at Kantar Health focused on early to late stage biotech/biopharma.

    Connie trained as a scientist and earned her Ph.D. in Microbiology and Immunology at UC Irvine and Bachelors of Arts in Molecular and Cellular Biology at UC Berkeley. She is passionate about translating innovative scientific discoveries into commercial products that impact patient lives.

    Panel Speaker: 


    Jennifer Shen, MD, MS

    Jennifer Shen is a physician scientist with extensive experience in both buy-side and sell-side business development. She also previously worked as a corporate venture investor at AstraZeneca, where she contributed to two Series A investments and spin-out deals, managed a $2 billion equity portfolio across 30 public companies, and served as a board observer for two stealth clinical stage biotech companies. Prior to AZ, Jennifer also held a role as a biotech equity researcher at the investment bank Needham and Co, responsible for IPOs of Moderna, Vaxcyte, and Pathom.

    Jennifer held a decade-long career as a medical professional and scientific researcher where earned an M.S. and completed a postdoctoral research fellowship at Stanford, followed by an M.D. from SUNY Buffalo. She also worked as a general surgery intern at USC and anesthesia resident at New York Medical College.



    RAVI KIRON, PhD, MBA

    Managing Director

    BioPharm Strategy

    Dr. Ravi Kiron (California, USA) is an experienced pharma/biotech/venture executive with decades experience Cornell U, Pfizer, J&J, Merck KGaA, biotech’s, in R&D, Clin Dev, IP, Tech, BD, M&A, IPO, Fund Raising, Consulting, Strategy, Commercialization, Entrepreneur & Cofounder, executing partnerships with academia, pharma & biotech, non-profit boards MIF, UCSD, UCD, NCI, Pantheon, BIO, BTS, biotech Board Advisory, leveraging his extensive global networks in CV, Onc Tarceva®, Neuro, Wound Healing, AI, Microbiome, Organoids, Fertility, Drug Del, Diag, Longevity. ​Dr. Kiron earned BS Chem, MS Microbio from Univ Mumbai, India; PhD Biochem from Indian Institute of Science, India; MBA from Rensselaer, NY, USA.


    Bin Cai, MBA

    Independent investor 

    Bringing over 10 years of leadership blending commercial and technical skills, I propel strategic efforts in oncology and chronic/rare diseases through launch planning, forecasting, and commercial analytics. I’m fueled by innovation and thrive on fostering multicultural collaboration and early-stage investment opportunities.

    Susan Zhou

    Director, Oncology Marketing – Pharma and Oncology Partnerships

    Natera

    Susan Zhou is a commercial strategist with experience in launching and driving adoption of emerging oncology products. At Natera, she leads marketing efforts for oncology clinical research partners, which includes helping pharmaceutical companies integrate circulating tumor DNA (ctDNA) testing, genomic profiling, and real-world data into clinical development and commercialization strategies. Susan specializes in translating complex concepts and scientific data into compelling narratives that drive engagement and adoption, ultimately supporting innovation to advance patient care in oncology.

    Previously, Susan was a strategy consultant at DeciBio, advising biopharma, diagnostics, and health technology companies on business, product development, and commercialization strategies. She holds a degree in Molecular and Cell Biology from UC Berkeley.


    For questions, please email: lu.lu@cabsweb.org 


    • April 26, 2025
    • 9:00 AM - 1:30 PM (PDT)
    • 1633 Old Bayshore Hwy #280, Burlingame, CA 94010

    CABS Clinical Development Workshop

    Date: April 26, 2025

    Time: 9:00 AM – 1:30 PM

    Location: 1633 Old Bayshore HWY #280, Burlingame, CA 94010

    Join Us for the CABS Clinical Development Workshop!

    Unlock the path to market approval! Gain valuable insights into clinical development from industry experts at Genentech and ChemoCentryx/Amgen. This half-day workshop will cover key aspects of clinical trials, including study design, statistical considerations, clinical pharmacology, and essential elements of clinical trial protocols. Don’t miss this opportunity to enhance your knowledge and expand your professional network! Register now!

    Workshop Agenda

    Speakers’ bios and phots:

    1. Shichang Miao, PhD

    Ex-VP PreclinDev & ClinPharm, ChemoCentryx/Amgen

    Dr Shichang Miao, PhD, is a seasoned DMPK/ClinPharm scientist and drug developer and biotech investor. During his career, he worked at several biotech companies in the San Francisco Bay Area, including Tularik, ChemoCentryx and Amgen. At ChemoCentryx, as Vice President of Preclinical Development & Clinical Pharmacology, he led a team to conduct the preclinical assessment and clinical pharmacology studies for the development of Tavneos® (avacopan), which was approved in 2021 by the FDA for the treatment of ANCA-associated vasculitis, leading to the acquisition of ChemoCentryx by Amgen in 2022. He received his PhD in organic chemistry and post-doctoral training in biochemistry at the University of British Columbia (Vancouver, Canada).

    Dr. Miao made significant contributions to the life science community; he is the founder and president of Pharmaceutical & Bioscience Society International (PBSS) and is a former president of the Chinese American BioPharmaceutical Society (CABS). He has also been serving as an advisor to Stanford University’s SPARK translational medicine program since 2015 and as a member of the screening committee of Life Science Angels, a leading life science angel investment group based in Silicon Valley, since 2018.

    2. Sara Glickstein Bar-Zeev, PhD

    Principal Clinical Scientist, Genentech

    Sara Glickstein Bar-Zeev, Ph.D., is a Principal Clinical Scientist in gRED OMNI Early Clinical Development, Genentech, Inc in South San Francisco.

    Her area of focus includes first-in-human and proof-of-concept clinical trials in non-oncology indications. She received her PhD at Cornell University in Neurobiology. Before joining Genentech in 2017, she spent a decade in Medical Communications, focusing on publication strategy and medical writing, and previously held research faculty positions at Cornell and Columbia Universities. She has completed fellowships in ophthalmology and psychiatry and has published more than 30 research papers during her time as an academic scientist.

    3. Chen Chen, PhD

    Principal Statistical Scientist, Genentech

    Chen Chen is a Principal Statistical Scientist in PDD Early Development Biometrics at Genentech, where he has worked since 2018. He has made significant contributions to molecule projects, research projects, and due diligence projects across multiple therapeutic areas, including ophthalmology, neuroscience, and immunology. Chen has effectively led data science teams through various stages of clinical development. In addition, he established collaborations with academic researchers in statistics and clinical development to explore and develop novel statistical methods and clinical techniques. Chen received his PhD in statistics from George Washington University and worked as a postdoctoral fellow at Penn State University before joining Genentech.

    A person standing in front of a waterfall AI-generated content may be incorrect.

    Please scan the QR code below to finish the registration!

      

    For questions, please email: liping.meng@cabsweb.org

    Sponsor: Sanyou Biopharmaceuticals Co., Ltd.





    • May 03, 2025
    • 8:00 AM - 6:00 PM (PDT)
    • Brentwood, CA

    Join Us for a Fun-Filled Fruit Picking Day!

    The Chinese American Biopharmaceutical Society (CABS) invites you and your family to a refreshing outdoor adventure in Brentwood!

    Date: Saturday, May 3
    Location: Brentwood, CA
    Fruits: Red Cherries, Mulberries, Strawberries
    Scan the QR code to RSVP and get more details! 

    Bring your sun hats, baskets, and good vibes — this is a perfect opportunity to enjoy nature, pick your favorite fruits, and connect with fellow CABS members and friends. Great for kids and adults alike!

    Don’t miss out on this sweet spring tradition!

    For any inquiries, please reach out to info@cabsweb.org.

    (We are currently seeking sponsors to support this impactful event. If your organization is interested in partnering with us, please reach out via email at fundraising@cabsweb.org.)




    • May 14, 2025
    • 4:00 PM - 7:30 PM (PDT)
    • Morrison Foerster Palo Alto office: 755 Page Mill Rd A, Palo Alto, CA 94304
    • 119

    Intellectual Property Essentials and Company Formation


    Morrison Foerster and CABS invite you to two exclusive workshops focused on one of the most critical pillars of life sciences—Intellectual Property (IP).

    • Do you ever find IP concepts overwhelming and difficult to navigate?

    • Are you considering or currently in the process of launching a company but not 100% where to begin?

    • Are you a business developer, investor, or exploring a transition into these roles? 

    • Or are you simply curious about the behind-the-scenes – how to license a IP from academia, what to watch out for, and what is the step-by-step process of building a company with the IP

    These expert-led, hands-on workshops will provide a clear roadmap for understanding IP fundamentals and the step-by-step process of company formation. Whether you're an entrepreneur, scientist, or industry professional, this series will equip you with the essential knowledge to build and protect innovation in the life sciences sector.

    Join us to gain practical insights, real-world strategies, and expert guidance to navigate the intersection of intellectual property and biotech entrepreneurship.


    Workshop 1: Patent Basics & IP Pitfalls to Avoid and IP Due Diligence 

    May 14 2025 (Wednesday)

    Morrison Foerster Palo Alto office:  755 Page Mill Rd A, Palo Alto, CA 94304


    Agenda: 

    4:00-4:30 Check-in and Introduction

    4:30-5:15 Patent Basics and How to Patent Life Sciences Inventions - Lisa Silverman

    5:15-6:00 IP Due Diligence and Unique Considerations For Cross-border Deals

     - Janet Xiao 

    6:00-6:30 Break 

    6:30-7:30 Panel discussion– What investors and potential partners will be looking at, in your IP portfolio? Panelist: Sue Xu, Alexis Ji, Janet Xiao, Lisa Silverman, Anna Yuan, Moderator: Kate You)



    Janet Xiao, Partner, Morrison Foerster

    Dr. Janet Xiao focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies to emerging startup companies. Recognized as being highly sought after for patent prosecution and strategy mandates, Janet develops and strengthens her clients’ complex patent portfolios to maximize commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. She also works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products.

    Lisa Silverman, Partner, Morrison Foerster

    Dr. Lisa Silverman’s practice focuses on patent portfolio management and strategic patent counseling in the areas of life sciences, pharmaceuticals, and chemistry. She has extensive experience in securing U.S. and global patent protection for pharmaceutical products and a deep understanding of patent lifecycle management and strategies for maximizing patent term and product exclusivity. She currently leads the firm’s Pharma Subgroup within the Patent Strategy + Prosecution practice group, and she is a member of the firm’s Life Sciences + Healthcare Leadership Team. Dr. Silverman works with clients on diverse technologies including small molecule pharmaceuticals, antibody-drug conjugates (ADCs), peptide therapeutics, pharmaceutical formulations and uses, drug-device combinations, clean technology, bioassays, and medical devices.


    Alexis Ji, Founder and Managing Partner, Primer Ventures

    Dr. Alexis Ji is the founder and managing partner of Primer Ventures, a life science venture capital firm focused on investing in disruptive early-stage companies in life science tools and therapeutics. Founded in 2023 in Silicon Valley, Primer Ventures has rapidly made its mark in backing exceptional entrepreneurs and startups to transform innovative science and technologies into groundbreaking products and therapies.

    Alexis brings two decades of expertise in venture capital and R&D in the biotech and genomics sectors. Before founding Primer Ventures, she spent over a decade at leading venture capital firms, including six years as a partner at Illumina Ventures, preceded by WuXi Ventures and ARCH Venture Partners. Her investment portfolio included early bets on industry disruptors such as Twist Bioscience (TWST) and Juno Therapeutics (JUNO, acquired by Celgene).  Alexis began her professional journey in biotech R&D at major companies including Merck, Roche, and Life Technologies (Thermo Fisher). 

    Alexis was featured by CNBC in its report on “11 women health tech VC investors” in 2017 and named a Rising Star by Global Corporate Venture in 2018 and 2019.  She holds a Ph.D. in Molecular Genetics from Washington University in St. Louis and an MBA from the University of Chicago Booth School of Business.



    Sue Xu, Managing Partner, Amino Capital


    Dr. Sue Xu is Managing Partner at Amino Capital, having joined the firm in 2012. She was the founding CEO of CandyHouse and CyteSi, both Stanford lab spin-offs. Since 2012, Sue has been actively involved in seed and Series A funding rounds, contributing to the success of around 20 unicorns and over 45 companies valued at more than $100 million. These include Chime, Rippling, Grail (acquired by Illumina), Webflow, Weee, DFINITY, Replit, Oasis Labs, OmiseGo, Turing, Wyze, GetAccept, Guesty, Instawork, Wetravel, StarRocks, Karbon Card, Unbabel, and WriteSonic.


    Sue has also addressed the United Nations on the role of AI in combating human trafficking and promoting the welfare of women and children. Her entrepreneurial journey began as the founding scientist of GlycoMira, and she has been involved in multiple lab spin-offs during her undergraduate and Ph.D. studies. Sue holds three patents, has authored over 20 journal articles, and was previously a medical researcher at Stanford University.

    Her investment focus spans data moats, network effects, and domain-agnostic opportunities. She has successfully guided startups from inception to unicorn status across sectors such as Generative AI, Consumer, SaaS, and Frontier tech.

    Sue has been featured on the Harvard HBS Women in VC Podcast and has guest lectured at Cornell’s MBA program on "Demystifying Big Data and FinTech." She is also a Visiting Professor at the University of Hong Kong for "Global Wealth Management" and has lectured at Georgetown University McDonough School of Business MBA program on “Myths and Truths: Entrepreneurship and Tech Development in China and the US.”

    Please scan the QR code below to finish the registration!

    We are currently seeking sponsors to support this impactful event. If your organization is interested in partnering with us, please reach out via email at fundraising@cabsweb.org.



    • September 13, 2025
    • 8:00 AM (PDT)
    • March 09, 2026
    • 6:00 PM (PDT)
    • South San Francisco Convention Center

    Welcome to 2025 BioPacific Conference  and thank you for sponsoring and exhibiting!

    This is Step 1. 

    To become a sponsor or exhibitor of 2025 CABS BioPacific Conference, please follow the steps below:

    1. Click the "Sponsor/Register" button at the right-corner and follow the step-by-step process to pay. The price will differ depends on level of sponsorship. Two payment methods:

    A. Pay by credit card.

    B. Pay by check. Click "invoice me" and then print out the invoice in your email. Mail the invoice together with the a check (payable to "CABS") to the following address: 268 Bush Street, #1888, San Francisco, CA 94104. U.S.A.

    2. You will receive an email to confirm your payment. High level sponsors will get free guest conference admission passes. Please go to Step 2 to register yourself and free guests for conference admission. 


    Any question? Please contact: fundraising@cabsweb.org  

    • September 13, 2025
    • 8:00 AM - 6:00 PM (PDT)
    • South San Francisco Conference Center, 255 S Airport Blvd, CA 94080

    Welcome to the CABS 2025 BioPacific Conference

    Date: September 13, 2025 

    Time: 8:00 am – @ 6:00 pm
    Location:  South San Francisco Conference Center, 255 S Airport Blvd, CA 94080

    Please save the date—registration will be opening soon!

    A white text on an orange background AI-generated content may be incorrect.

    We are thrilled to announce that CABS will host the 2025 BioPacific Conference on September 13th, 2025, at the South San Francisco Conference Center, themed “Frontiers in Healthcare: The Interplay of Science Innovation, Business, and Policy ". We look forward to welcoming you to this exciting conference!

    We are currently seeking additional sponsors to support this impactful event. If your organization is interested in partnering with us, please reach out via email at fundraising@cabsweb.org.

    A table with text and numbers Description automatically generated with medium confidence







Powered by Wild Apricot Membership Software